Why are ResMed shares tumbling on Monday?

This medical device company's shares are missing out on the good times today.

| More on:
A man slumps crankily over his morning coffee as it pours with rain outside.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be charging higher on Monday, but the same cannot be said for ResMed Inc. (ASX: RMD) shares.

In morning trade, the sleep disorder treatment company's shares are down 3.5% to $31.27.

Why are ResMed shares under pressure?

Today's weakness follows a heavy decline by the company's NYSE listed shares on Friday night.

Investors were hitting the sell button on Wall Street amid concerns over the impact that weight loss drugs could have on demand.

This was driven by the release of an update from DexCom Inc (NASDAQ: DXCM), which sent its shares crashing 40% into the red, knocking US$17 billion off its market capitalisation.

While DexCom is a blood sugar monitoring device manufacturer and therefore operating in a different market to ResMed, there are potentially some overlaps in their customer bases.

Dexcom makes glucose monitors that are essential for type 1 diabetics. It also sells to people with the more common type 2 diabetes, which is driven by weight. The latter is also a cause of sleep apnoea, which ResMed's devices treat.

According to Bloomberg, the San Diego-based medical device manufacturer blamed a drop in new customers, lower revenue per patient, and higher-than-expected rebates for its decision to downgrade its revenue guidance by as much as US$350 million.

Commenting on the update, Jared Holz from Mizuho Securities, said:

It is strange that the wheels came off this bus so abruptly. The speed at which the business appears to have deteriorated is borderline stunning.

This sentiment was echoed by Robbie Marcus from JP Morgan. He said:

There's no getting away from the fact that this Thursday's update was a sharp turn in the wrong direction for Dexcom. Investor faith in management has been severely shaken, especially following reiterated guidance at a June competitor conference before a bullish ADA.

Time to panic?

There are potentially two reasons not to panic.

One is that this downgrade could prove to be company specific. That's because DexCom's rival, Insulet Corp (NASDAQ: PODD) is continuing to perform strongly. In fact, it released its second quarter update on Friday and delivered sales ahead of expectations.

Furthermore, Abbott Laboratories (NYSE: ABT), which is another competitor, raised its full year profit guidance thanks partly to strong glucose monitor sales.

This appears to indicate that Dexcom is losing market share to other medical device manufacturers, rather than to weight loss drugs.

Another reason to remain positive on ResMed shares is that most analysts agree that the company can continue to grow at a solid rate long into the future even if weight loss drug reduce its addressable market.

As a result, this weakness could prove to be a buying opportunity for patient long-term focused investors.

ResMed is releasing its quarterly update on Friday.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Abbott Laboratories and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended DexCom and Insulet. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended DexCom. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »